1299 related articles for article (PubMed ID: 31651347)
41. Role of microRNAs in the development of hepatocellular carcinoma and drug resistance.
Tricoli L; Niture S; Chimeh U; Ressom H; Kumar D
Front Biosci (Landmark Ed); 2019 Jan; 24(2):382-391. PubMed ID: 30468662
[TBL] [Abstract][Full Text] [Related]
42. Behind the curtain of non-coding RNAs; long non-coding RNAs regulating hepatocarcinogenesis.
El Khodiry A; Afify M; El Tayebi HM
World J Gastroenterol; 2018 Feb; 24(5):549-572. PubMed ID: 29434445
[TBL] [Abstract][Full Text] [Related]
43. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7.
Feng X; Zou B; Nan T; Zheng X; Zheng L; Lan J; Chen W; Yu J
Int J Med Sci; 2022; 19(2):257-266. PubMed ID: 35165511
[TBL] [Abstract][Full Text] [Related]
44. Four long noncoding RNAs as potential prognostic biomarkers for hepatocellular carcinoma.
Wang J; Pu J; Yao T; Lu X; Deng Y
J Cell Physiol; 2019 Jun; 234(6):8709-8716. PubMed ID: 30417366
[TBL] [Abstract][Full Text] [Related]
45. Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review).
Chen C; Tang X; Liu Y; Zhu J; Liu J
Int J Oncol; 2019 May; 54(5):1511-1524. PubMed ID: 30896792
[TBL] [Abstract][Full Text] [Related]
46. Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells.
Huo X; Han S; Wu G; Latchoumanin O; Zhou G; Hebbard L; George J; Qiao L
Mol Cancer; 2017 Oct; 16(1):165. PubMed ID: 29061150
[TBL] [Abstract][Full Text] [Related]
47. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.
Kong H; Sun J; Zhang W; Zhang H; Li H
Bioengineered; 2022 Feb; 13(2):3108-3121. PubMed ID: 35037556
[TBL] [Abstract][Full Text] [Related]
48. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines.
Zhang Z; He CZ; Qin YQ; Liao JJ; Huang ST; Mo S; Li HM; Lin JY
Aging (Albany NY); 2020 Nov; 12(23):24255-24269. PubMed ID: 33234725
[TBL] [Abstract][Full Text] [Related]
49. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
Wang Y; Tan K; Hu W; Hou Y; Yang G
Exp Cell Res; 2022 Nov; 420(1):113335. PubMed ID: 36084669
[TBL] [Abstract][Full Text] [Related]
50. The role of long noncoding RNAs in hepatocellular carcinoma.
Huang Z; Zhou JK; Peng Y; He W; Huang C
Mol Cancer; 2020 Apr; 19(1):77. PubMed ID: 32295598
[TBL] [Abstract][Full Text] [Related]
51. The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma.
Hu X; Zhu H; Shen Y; Zhang X; He X; Xu X
Front Oncol; 2021; 11():696705. PubMed ID: 34367979
[TBL] [Abstract][Full Text] [Related]
52. Long Non-Coding RNAs as Mediators of Tumor Microenvironment and Liver Cancer Cell Communication.
Lin YH; Wu MH; Yeh CT; Lin KH
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30477236
[TBL] [Abstract][Full Text] [Related]
53. Long non-coding RNAs: critical players in hepatocellular carcinoma.
Sun J; Bie B; Zhang S; Yang J; Li Z
Int J Mol Sci; 2014 Nov; 15(11):20434-48. PubMed ID: 25387074
[TBL] [Abstract][Full Text] [Related]
54. Long non-coding RNAs as targets for immunosuppressive drug teriflunomide in anti-cancer potential for hepatocellular carcinoma.
Xu Y; Shen D; Liu J; Xu X; Tu J; Qin L; Jiang L; Qian H; Guo F
J Mol Histol; 2020 Dec; 51(6):659-673. PubMed ID: 33034797
[TBL] [Abstract][Full Text] [Related]
55. LncRNA DGCR5 represses the development of hepatocellular carcinoma by targeting the miR-346/KLF14 axis.
Wang YG; Liu J; Shi M; Chen FX
J Cell Physiol; 2018 Jan; 234(1):572-580. PubMed ID: 30216442
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
57. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
58. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
[TBL] [Abstract][Full Text] [Related]
59. Role of microRNA and Long Non-Coding RNA in Hepatocellular Carcinoma.
Gupta M; Chandan K; Sarwat M
Curr Pharm Des; 2020; 26(4):415-428. PubMed ID: 31939724
[TBL] [Abstract][Full Text] [Related]
60. Overexpression of Long Non-Coding RNA MEG3 Inhibits Proliferation of Hepatocellular Carcinoma Huh7 Cells via Negative Modulation of miRNA-664.
He JH; Han ZP; Liu JM; Zhou JB; Zou MX; Lv YB; Li YG; Cao MR
J Cell Biochem; 2017 Nov; 118(11):3713-3721. PubMed ID: 28374914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
